Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

107.02 -1.93 (-1.77%)
Streaming Delayed Price Updated: 3:30 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
45 46 Next >
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several... 
Via Benzinga
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen  
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Is This Big Pharma Stock a Buy for Dividend Investors?
The Swiss pharmaceutical giant possesses a tremendous product pipeline. 
Via The Motley Fool
Why Novartis Stock Is Trading Higher Today
Via Benzinga
Earnings Preview: Novartis
Via Benzinga
New York Rep. Daniel Goldman Bought Over $50K Worth of Novartis Stock: Here's What You Should Know
Via Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels
Novartis AG (NYSE: NVS) released detailed  
Via Benzinga
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines
In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam. 
Via Benzinga
Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise
Novartis stock popped on its guidance boost early Tuesday after the company beat first-quarter expectations. 
Via Investor's Business Daily
Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment
Via Benzinga
Why Shares of Legend Biotech Jumped Wednesday
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt. 
Via The Motley Fool
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland
Via Investor Brand Network
2 Best Biotech Stocks to Buy for the Long Haul
These two are among the largest pharma companies in the world. 
Via The Motley Fool
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards. 
Via InvestorPlace
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
Via Benzinga
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or... 
Via Benzinga
Trillions In Biotech Stock Gains Trace Back To This Financier
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider. 
Via Investor's Business Daily
Epic Growth Story Predicted for Pharmaceutical Drug Delivery Market's Future: Johnson & Johnson, Novartis International, Merck
Stay up-to-date with Pharmaceutical Drug Delivery Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher
Tilray Brands moves lower on mixed results, but the bottom may be in, with positive FCF expected this quarter. The long-term catalyst is US legalization. 
Via MarketBeat
Topics Cannabis
Exposures Cannabis
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
Shares are closing in on a buy point out of a consolidation. 
Via Investor's Business Daily
Pediatric Drugs Market Giants Spending Is Going to Boom : Pfizer, Bayer, Abbott Laboratories, Merck
NJ New Jersey, USA -- (SBWIRE) -- 04/10/2023 -- Latest Study on Industrial Growth of Pediatric Drugs Market 2022-2027. A detailed study accumulated to offer Latest insights about acute features of the... 
Via SBWire
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.  
Via Benzinga
Novartis Shares Leap On Positive Clinical Trial Data
Swiss pharmaceutical giant Novartis leaped 5.11% in the past week following news that its Kisqali breast-cancer treatment cut the probability of relapse. 
Via MarketBeat
6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative'
Rocket Pharma (NASDAQ: RCKT) CEO Gaurav Shah is on a mission to "change the narrative" when it comes to rare diseases. 
Via Benzinga
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.